{"id":839907,"date":"2026-10-07T03:59:02","date_gmt":"2026-10-07T03:59:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=839907"},"modified":"2026-10-07T03:59:02","modified_gmt":"2026-10-07T03:59:02","slug":"focal-segmental-glomerulosclerosis-market-to-expand-rapidly-with-advancing-pipeline-and-increasing-treatment-adoption-by-2036-delveinsight-retrophin-abbvie-astrazeneca-pfizer-sanofi-teva","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/focal-segmental-glomerulosclerosis-market-to-expand-rapidly-with-advancing-pipeline-and-increasing-treatment-adoption-by-2036-delveinsight-retrophin-abbvie-astrazeneca-pfizer-sanofi-teva_839907.html","title":{"rendered":"Focal Segmental Glomerulosclerosis Market to Expand Rapidly with Advancing Pipeline and Increasing Treatment Adoption by 2036 \u2013 DelveInsight | Retrophin, AbbVie, AstraZeneca, Pfizer, Sanofi, Teva"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/upload\/2026\/10\/1791225595.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Focal Segmental Glomerulosclerosis Market to Expand Rapidly with Advancing Pipeline and Increasing Treatment Adoption by 2036 &ndash; DelveInsight | Retrophin, AbbVie, AstraZeneca, Pfizer, Sanofi, Teva\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/10\/1791225595.jpg\" alt=\"Focal Segmental Glomerulosclerosis Market to Expand Rapidly with Advancing Pipeline and Increasing Treatment Adoption by 2036 &ndash; DelveInsight | Retrophin, AbbVie, AstraZeneca, Pfizer, Sanofi, Teva\" width=\"225\" height=\"125\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">(Albany, New York) &#8211; October 07, 2026: The Key Focal Segmental Glomerulosclerosis Companies in the market include &#8211; Evergreen Therapeutics, Certa Therapeutics, River 3 Renal Corp, Boehringer Ingelheim, Dimerix Bioscience, Travere Therapeutics, Dimerix, Goldfinch Bio, Vertex Pharmaceuticals, GlaxoSmithKline, Dimerix Bioscience Pty Ltd, ChemoCentryx, AstraZeneca, Genentech, Inc., Sanofi, Mallinckrodt ARD LLC, ACELYRIN Inc., Kyowa Kirin Co., Ltd., Bristol-Myers Squibb, and others.<\/div>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s <strong>&ldquo;Focal Segmental Glomerulosclerosis Market Insights, Epidemiology, and Market Forecast-2036&Prime;<\/strong> report offers an in-depth understanding of the Focal Segmental Glomerulosclerosis, historical and forecasted epidemiology as well as the Focal Segmental Glomerulosclerosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get a Free sample for the Focal Segmental Glomerulosclerosis Market Report:<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/focal-segmental-glomerulosclerosis-fsgs-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gaurav\">https:\/\/www.delveinsight.com\/report-store\/focal-segmental-glomerulosclerosis-fsgs-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key facts of the Focal Segmental Glomerulosclerosis Market Report: <\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>The Focal Segmental Glomerulosclerosis market size was valued approximately <strong>USD 734 Million in 2022<\/strong> and is anticipated to grow with a significant <strong>CAGR<\/strong> during the study period (2022-2036).<\/p>\n<\/li>\n<li>\n<p><strong>In September 2026, BI 764198:<\/strong> The Phase III PODOMOUNT-pFSGS trial remained actively recruiting. The study is evaluating once-daily oral BI 764198 versus placebo for up to 104 weeks in adults and adolescents with primary or TRPC6-related genetic FSGS.<\/p>\n<\/li>\n<li>\n<p><strong>In August 2026, APL2 (Apellis Pharmaceuticals):<\/strong> The company&#8217;s sequential Phase II\/III study of APL2 in FSGS was updated, with the program designed to evaluate complement C3 inhibition in adults and adolescents. The Phase II portion is planned to precede the randomized Phase III portion.<\/p>\n<\/li>\n<li>\n<p><strong>In August 2026, Praliciguat:<\/strong> The Phase II FSGS study remained actively recruiting, evaluating praliciguat versus placebo in adults with biopsy-confirmed FSGS.<\/p>\n<\/li>\n<li>\n<p><strong>In June 2026, DMX-200:<\/strong> Dimerix entered an exclusive licensing agreement with Everest Medicines for DMX-200 in Greater China, South Korea and Southeast Asia. The ACTION3 Phase III trial was reported as fully recruited across 21 countries.<\/p>\n<\/li>\n<li>\n<p><strong>In January 2026, Praliciguat (Akebia Therapeutics):<\/strong> The first patient was dosed in a Phase II study evaluating praliciguat in adults with biopsy-confirmed FSGS. The randomized, placebo-controlled study is designed to assess efficacy and safety over 24 weeks, followed by an open-label extension.<\/p>\n<\/li>\n<li>\n<p><strong>In July 2026, Boehringer Ingelheim<\/strong> has begun enrolling patients in the Phase II NCT07220083 clinical trial evaluating BI 764198 for the treatment of primary focal segmental glomerulosclerosis (FSGS) in adults and adolescents. The study aims to evaluate the investigational therapy&#8217;s safety, efficacy, and potential to reduce proteinuria while preserving kidney function, offering a promising approach for patients with this rare kidney disorder.<\/p>\n<\/li>\n<li>\n<p><strong>In June 2026, The U.S. Food and Drug Administration (FDA) approved FILSPARI&reg; (sparsentan)<\/strong> to reduce proteinuria in adults and children aged 8 years and older with primary focal segmental glomerulosclerosis (FSGS), marking the first FDA-approved treatment specifically indicated for this rare kidney disease. According to Travere Therapeutics, more than 30,000 individuals in the United States are estimated to be living with FSGS without nephrotic syndrome, highlighting the significant unmet medical need addressed by this approval.<\/p>\n<\/li>\n<li>\n<p><strong>In May 2026, Travere Therapeutics<\/strong> presented long-term clinical data demonstrating that FILSPARI (sparsentan) provides durable reductions in proteinuria among patients with primary focal segmental glomerulosclerosis (FSGS), further supporting its potential as a disease-modifying therapy. Following its regulatory approval, the company also reaffirmed its commitment to increasing disease awareness and improving patient access to the treatment through ongoing post-approval initiatives.<\/p>\n<\/li>\n<li>\n<p><strong>In April 2026, Travere Therapeutics, Inc. (TVTX)<\/strong> announced that the U.S. Food and Drug Administration (FDA) has approved Filspari to reduce proteinuria in certain adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis (FSGS). This marks Filspari as the first FDA-approved therapy specifically indicated for this condition. The company estimates that more than 30,000 individuals in the United States are living with FSGS without nephrotic syndrome. Prior to this approval, Filspari had already received FDA authorization for the treatment of IgA nephropathy.<\/p>\n<\/li>\n<li>\n<p><strong>In January 2026, The U.S. FDA<\/strong> has extended the review timeline for the supplemental New Drug Application (sNDA) of sparsentan (Filspari) for focal segmental glomerulosclerosis (FSGS). Travere Therapeutics, Inc. confirmed that the Prescription Drug User Fee Act (PDUFA) target action date has been moved from January 13, 2026, to April 13, 2026. No additional requests regarding the drug&rsquo;s safety or manufacturing have been made.<\/p>\n<\/li>\n<li>\n<p><strong>In January 2026, Akebia Therapeutics<\/strong> announced that the first patient has been dosed in a Phase II clinical trial of praliciguat for the treatment of biopsy-confirmed FSGS.<\/p>\n<\/li>\n<li>\n<p><strong>In December 2025, Dimerix<\/strong> announced that it had received feedback from the US FDA on the clinical appropriateness of proteinuria reduction as an endpoint for full approval of DMX-200 in the ACTION3 Phase III trial in patients with FSGS. Dimerix plans to submit the requested information to the FDA ahead of the blinded statistical powering analysis and required ACTION3 protocol updates, with the analysis now expected in early 2026.<\/p>\n<\/li>\n<li>\n<p><strong>In September 2025, Travere Therapeutics, Inc. (Nasdaq: TVTX)<\/strong> announced that the U.S. Food and Drug Administration (FDA) has notified the company that, after additional evaluation of the supplemental New Drug Application (sNDA) for FILSPARI&reg; (sparsentan) in focal segmental glomerulosclerosis (FSGS), an advisory committee meeting will no longer be required. The sNDA continues under FDA review, with a Prescription Drug User Fee Act (PDUFA) target action date set for January 13, 2026.<\/p>\n<\/li>\n<li>\n<p><strong>In June 2025, The DUPLEX trial (NCT03493685)<\/strong> demonstrated that sparsentan, a dual endothelin-angiotensin receptor antagonist, resulted in a sustained reduction in proteinuria among patients with focal segmental glomerulosclerosis (FSGS).<\/p>\n<\/li>\n<li>\n<p>In May 2025, Travere Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for FILSPARI (sparsentan), seeking full approval for the treatment of focal segmental glomerulosclerosis (FSGS).<\/p>\n<\/li>\n<li>\n<p>In April 2025, Dimerix Limited and Amicus Therapeutics announced an exclusive licensing agreement granting Amicus the rights to commercialize Dimerix&rsquo;s Phase III drug candidate, DMX-200, in the U.S. for all indications, including FSGS. Dimerix will maintain commercialization rights for DMX-200 in all regions outside the U.S.<\/p>\n<\/li>\n<li>\n<p>In March 2025, Travere Therapeutics, Inc. announced that it will present three abstracts, including a late-breaking oral presentation, at the 2025 National Kidney Foundation (NKF) Spring Clinical Meetings, scheduled for April 10&ndash;13 in Boston, MA. The late-breaking session will showcase new analyses from the Phase III DUPLEX Study of FILSPARI&reg; (sparsentan) in focal segmental glomerulosclerosis (FSGS), highlighting that partial and complete proteinuria remission occurred earlier and more frequently with FILSPARI compared to irbesartan. The data also indicated that patients achieving proteinuria remission experienced low rates of kidney failure.<\/p>\n<\/li>\n<li>\n<p>According to estimates, the total FSGS market size in 7MM was approximately USD 300 million in 2025, with the United States accounting for the largest share, and the market is projected to grow at a significant CAGR through 2036.<\/p>\n<\/li>\n<li>\n<p>In 2025, among the EU4 and the UK, the UK held the largest market share, followed by Germany, while Italy accounted for the smallest share.<\/p>\n<\/li>\n<li>\n<p>According to analysis, in 2025, the total diagnosed prevalent cases of FSGS in the 7MM were approximately 213,000 and are expected to increase through 2036.<\/p>\n<\/li>\n<li>\n<p>The United States accounted for the highest diagnosed prevalent cases of FSGS, representing approximately 36% of total cases in the 7MM in 2025.<\/p>\n<\/li>\n<li>\n<p>Among the EU4 and the UK, the UK accounted for the highest diagnosed prevalent cases of FSGS in 2025, followed by Germany.<\/p>\n<\/li>\n<li>\n<p>The prevalence of FSGS was the highest in individuals aged 18&ndash;64.<\/p>\n<\/li>\n<li>\n<p>In 2025, primary FSGS was found to be the more prevalent type among the two forms of FSGS, accounting for approximately 80% of the diagnosed population in the United States.<\/p>\n<\/li>\n<li>\n<p>DelveInsight estimates that Japan has more diagnosed prevalent cases of FSGS in males (61%) than females (39%)<\/p>\n<\/li>\n<li>\n<p><strong>Key Focal Segmental Glomerulosclerosis Companies:<\/strong> Evergreen Therapeutics, Certa Therapeutics, River 3 Renal Corp, Boehringer Ingelheim, Dimerix Bioscience, Travere Therapeutics, Dimerix, Goldfinch Bio, Vertex Pharmaceuticals, GlaxoSmithKline, Dimerix Bioscience Pty Ltd, ChemoCentryx, AstraZeneca, Genentech, Inc., Sanofi, Mallinckrodt ARD LLC, ACELYRIN Inc., Kyowa Kirin Co., Ltd., Bristol-Myers Squibb, and others<\/p>\n<\/li>\n<li>\n<p><strong>Key Focal Segmental Glomerulosclerosis Therapies:<\/strong> EG-102, OCX-063, R3R 01, BI764198, DMX-200, GFB-887, VX-147, Losmapimod, Propagermanium, RE-021 (Sparsentan), CCX140-B, Dapagliflozin, rituximab, fresolimumab, Acthar Gel, VB119, Bleselumab, Abatacept, and others<\/p>\n<\/li>\n<li>\n<p>The Focal Segmental Glomerulosclerosis epidemiology based on gender analyzed that Focal Segmental Glomerulosclerosis is more prevalent in males than females in the United States<\/p>\n<\/li>\n<li>\n<p>The Focal Segmental Glomerulosclerosis market is expected to surge due to the disease&#8217;s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Focal Segmental Glomerulosclerosis pipeline products will significantly revolutionize the Focal Segmental Glomerulosclerosis market dynamics.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Focal Segmental Glomerulosclerosis Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Focal Segmental Glomerulosclerosis (FSGS) is a rare kidney disorder characterized by scarring (sclerosis) of some of the kidney&#8217;s glomeruli, which are the small filtering units. This scarring can lead to protein leakage into the urine, kidney dysfunction, and eventually kidney failure if untreated. FSGS can be primary (idiopathic) or secondary, caused by other conditions like infections, obesity, or genetic factors. Symptoms may include swelling, high blood pressure, and foamy urine. Treatment typically involves managing symptoms and preventing further kidney damage.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To Know in detail about the Focal Segmental Glomerulosclerosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/focal-segmental-glomerulosclerosis-fsgs-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gaurav\">Focal Segmental Glomerulosclerosis Market Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Focal Segmental Glomerulosclerosis Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\">The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Focal Segmental Glomerulosclerosis Epidemiology Segmentation:<\/strong><\/p>\n<p style=\"text-align: justify;\">The Focal Segmental Glomerulosclerosis market report proffers epidemiological analysis for the study period 2022&ndash;2036 in the 7MM segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Total Prevalence of Focal Segmental Glomerulosclerosis<\/p>\n<\/li>\n<li>\n<p>Prevalent Cases of Focal Segmental Glomerulosclerosis by severity<\/p>\n<\/li>\n<li>\n<p>Gender-specific Prevalence of Focal Segmental Glomerulosclerosis<\/p>\n<\/li>\n<li>\n<p>Diagnosed Cases of Episodic and Chronic Focal Segmental Glomerulosclerosis<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download the report to understand which factors are driving Focal Segmental Glomerulosclerosis epidemiology trends @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/focal-segmental-glomerulosclerosis-fsgs-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gaurav\">Focal Segmental Glomerulosclerosis Epidemiology Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Focal Segmental Glomerulosclerosis Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n<p style=\"text-align: justify;\">The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Focal Segmental Glomerulosclerosis market or expected to get launched during the study period. The analysis covers Focal Segmental Glomerulosclerosis market uptake by drugs, patient uptake by therapies, and sales of each drug.<\/p>\n<p style=\"text-align: justify;\">Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.<\/p>\n<p style=\"text-align: justify;\">The report also covers the Focal Segmental Glomerulosclerosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Focal Segmental Glomerulosclerosis Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Praliciguat: Akebia Therapeutics<\/p>\n<\/li>\n<li>\n<p>EG-102: Evergreen Therapeutics<\/p>\n<\/li>\n<li>\n<p>OCX-063: Certa Therapeutics<\/p>\n<\/li>\n<li>\n<p>R3R 01: River 3 Renal Corp<\/p>\n<\/li>\n<li>\n<p>BI764198: Boehringer Ingelheim<\/p>\n<\/li>\n<li>\n<p>DMX200: Dimerix Bioscience<\/p>\n<\/li>\n<li>\n<p>Sparsentan: Travere Therapeutics<\/p>\n<\/li>\n<li>\n<p>DMX-200: Dimerix<\/p>\n<\/li>\n<li>\n<p>GFB-887: Goldfinch Bio<\/p>\n<\/li>\n<li>\n<p>VX-147: Vertex Pharmaceuticals<\/p>\n<\/li>\n<li>\n<p>Losmapimod: GlaxoSmithKline<\/p>\n<\/li>\n<li>\n<p>Propagermanium: Dimerix Bioscience Pty Ltd<\/p>\n<\/li>\n<li>\n<p>RE-021 (Sparsentan): Travere Therapeutics, Inc.<\/p>\n<\/li>\n<li>\n<p>CCX140-B: ChemoCentryx<\/p>\n<\/li>\n<li>\n<p>Dapagliflozin: AstraZeneca<\/p>\n<\/li>\n<li>\n<p>rituximab: Genentech, Inc.<\/p>\n<\/li>\n<li>\n<p>fresolimumab: Sanofi<\/p>\n<\/li>\n<li>\n<p>Acthar Gel: Mallinckrodt ARD LLC<\/p>\n<\/li>\n<li>\n<p>VB119: ACELYRIN Inc.<\/p>\n<\/li>\n<li>\n<p>Bleselumab: Kyowa Kirin Co., Ltd.<\/p>\n<\/li>\n<li>\n<p>Abatacept: Bristol-Myers Squibb<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about therapies set to grab major Focal Segmental Glomerulosclerosis market share @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/focal-segmental-glomerulosclerosis-fsgs-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gaurav\">Focal Segmental Glomerulosclerosis Treatment Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Focal Segmental Glomerulosclerosis Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Increasing prevalence of chronic kidney diseases and rare glomerular disorders is expanding the patient pool for FSGS therapies.<\/p>\n<\/li>\n<li>\n<p>Growing awareness and improved diagnostic capabilities, including genetic testing and kidney biopsy techniques, are supporting earlier and more accurate diagnosis.<\/p>\n<\/li>\n<li>\n<p>Advancements in targeted and precision medicine approaches are driving the development of novel therapies aimed at underlying disease mechanisms.<\/p>\n<\/li>\n<li>\n<p>A robust pipeline of emerging treatments, including endothelin receptor antagonists, APOL1-targeted therapies, and immunomodulators, is fueling market growth.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Focal Segmental Glomerulosclerosis Market Barriers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>The rarity and heterogeneity of FSGS make patient identification, diagnosis, and clinical trial recruitment challenging.<\/p>\n<\/li>\n<li>\n<p>Limited availability of approved disease-specific therapies results in continued reliance on supportive care and off-label treatments.<\/p>\n<\/li>\n<li>\n<p>High costs associated with novel therapies and long-term disease management may restrict patient access and reimbursement.<\/p>\n<\/li>\n<li>\n<p>Variability in disease progression and treatment response complicates clinical development and therapeutic decision-making.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Focal Segmental Glomerulosclerosis Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p><strong>Study Period: 2022&ndash;2036<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>Coverage:<\/strong> 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]<\/p>\n<\/li>\n<li>\n<p><strong>Key Focal Segmental Glomerulosclerosis Companies:<\/strong> Evergreen Therapeutics, Certa Therapeutics, River 3 Renal Corp, Boehringer Ingelheim, Dimerix Bioscience, Travere Therapeutics, Dimerix, Goldfinch Bio, Vertex Pharmaceuticals, GlaxoSmithKline, Dimerix Bioscience Pty Ltd, ChemoCentryx, AstraZeneca, Genentech, Inc., Sanofi, Mallinckrodt ARD LLC, ACELYRIN Inc., Kyowa Kirin Co., Ltd., Bristol-Myers Squibb, and others<\/p>\n<\/li>\n<li>\n<p><strong>Key Focal Segmental Glomerulosclerosis Therapies:<\/strong> EG-102, OCX-063, R3R 01, BI764198, DMX-200, GFB-887, VX-147, Losmapimod, Propagermanium, RE-021 (Sparsentan), CCX140-B, Dapagliflozin, rituximab, fresolimumab, Acthar Gel, VB119, Bleselumab, Abatacept, and others<\/p>\n<\/li>\n<li>\n<p><strong>Focal Segmental Glomerulosclerosis Therapeutic Assessment:<\/strong> Focal Segmental Glomerulosclerosis current marketed and Focal Segmental Glomerulosclerosis emerging therapies<\/p>\n<\/li>\n<li>\n<p><strong>Focal Segmental Glomerulosclerosis Market Dynamics:<\/strong> Focal Segmental Glomerulosclerosis market drivers and Focal Segmental Glomerulosclerosis market barriers<\/p>\n<\/li>\n<li>\n<p><strong>Competitive Intelligence Analysis:<\/strong> SWOT analysis, PESTLE analysis, Porter&rsquo;s five forces, BCG Matrix, Market entry strategies<\/p>\n<\/li>\n<li>\n<p><strong>Focal Segmental Glomerulosclerosis Unmet Needs, KOL&rsquo;s views, Analyst&rsquo;s views, Focal Segmental Glomerulosclerosis Market Access and Reimbursement <\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To know more about Focal Segmental Glomerulosclerosis companies working in the treatment market, visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/focal-segmental-glomerulosclerosis-fsgs-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gaurav\">Focal Segmental Glomerulosclerosis Clinical Trials and Therapeutic Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents <\/strong><\/p>\n<p style=\"text-align: justify;\">1. Focal Segmental Glomerulosclerosis Market Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary for Focal Segmental Glomerulosclerosis<\/p>\n<p style=\"text-align: justify;\">3. SWOT analysis of Focal Segmental Glomerulosclerosis<\/p>\n<p style=\"text-align: justify;\">4. Focal Segmental Glomerulosclerosis Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Focal Segmental Glomerulosclerosis Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">6. Focal Segmental Glomerulosclerosis Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">7. Focal Segmental Glomerulosclerosis Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Country-Specific Patient Population of Focal Segmental Glomerulosclerosis<\/p>\n<p style=\"text-align: justify;\">9. Focal Segmental Glomerulosclerosis Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify;\">10. Focal Segmental Glomerulosclerosis Unmet Needs<\/p>\n<p style=\"text-align: justify;\">11. Focal Segmental Glomerulosclerosis Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">12. Focal Segmental Glomerulosclerosis Market Outlook<\/p>\n<p style=\"text-align: justify;\">13. Country-Wise Focal Segmental Glomerulosclerosis Market Analysis (2022&ndash;2036)<\/p>\n<p style=\"text-align: justify;\">14. Focal Segmental Glomerulosclerosis Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify;\">15. Focal Segmental Glomerulosclerosis Market Drivers<\/p>\n<p style=\"text-align: justify;\">16. Focal Segmental Glomerulosclerosis Market Barriers<\/p>\n<p style=\"text-align: justify;\">17. Focal Segmental Glomerulosclerosis Appendix<\/p>\n<p style=\"text-align: justify;\">18. Focal Segmental Glomerulosclerosis Report Methodology<\/p>\n<p style=\"text-align: justify;\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">20. Disclaimer<\/p>\n<p style=\"text-align: justify;\">21. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight <\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p style=\"text-align: justify;\">It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_72253.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Gaurav Bora<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=focal-segmental-glomerulosclerosis-market-to-expand-rapidly-with-advancing-pipeline-and-increasing-treatment-adoption-by-2036-delveinsight-retrophin-abbvie-astrazeneca-pfizer-sanofi-teva\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=focal-segmental-glomerulosclerosis-market-to-expand-rapidly-with-advancing-pipeline-and-increasing-treatment-adoption-by-2036-delveinsight-retrophin-abbvie-astrazeneca-pfizer-sanofi-teva\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>(Albany, New York) &#8211; October 07, 2026: The Key Focal Segmental Glomerulosclerosis Companies in the market include &#8211; Evergreen Therapeutics, Certa Therapeutics, River 3 Renal Corp, Boehringer Ingelheim, Dimerix Bioscience, Travere Therapeutics, Dimerix, Goldfinch Bio, Vertex Pharmaceuticals, GlaxoSmithKline, Dimerix Bioscience &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/focal-segmental-glomerulosclerosis-market-to-expand-rapidly-with-advancing-pipeline-and-increasing-treatment-adoption-by-2036-delveinsight-retrophin-abbvie-astrazeneca-pfizer-sanofi-teva_839907.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-839907","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/839907","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=839907"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/839907\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=839907"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=839907"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=839907"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}